Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer

BACKGROUND: The effectiveness of sacituzumab govitecan for metastatic triple-negative breast cancer (TNBC) has been reported in recent research, however, the value of the effectiveness and cost of sacituzumab govitecan is still unclear. METHODS: A microsimulation model was developed using data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jiao, Li, SiNi, Li, YaMin, Li, JianHe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308729/
https://www.ncbi.nlm.nih.gov/pubmed/37386633
http://dx.doi.org/10.1186/s12913-023-09728-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308729/
https://www.ncbi.nlm.nih.gov/pubmed/37386633
http://dx.doi.org/10.1186/s12913-023-09728-6

Ejemplares similares